Cord Blood Transplant with Abatacept and Low-Dose ATG for TP53-Mutated Complex Karyotype AML: A Single-Center Report

Key Points

• Cord blood transplant with abatacept and low-dose ATG showed improved outcomes in TP53-mutated AML.
• The combination treatment led to significant survival rates, with 80% of patients alive at one year.
• Observational analysis at a single center included patients with complex karyotype AML, focusing on their response to the treatment.
• Implications highlight the need for further studies to validate efficacy and explore long-term effects of the approach.